





Challenges of implementing PV processes in Mena region

Mohammed Ashar

Jamjoom pharma,Saudi Arabia.

Pharmacovigilance has received much attention in MENA region countries recently due to the development of new regulations. Only approximately half of Arab countries are official members of the World Health Organization (WHO) Collaborating Centre for International Drug Monitoring. Countries such as Saudi Arabia, Morocco, Tunisia, Egypt, and Jordan are considered to be relatively advanced pharmacovigilance countries, whereas other countries such as Libya, Yemen, and Palestine remain in the very early stages of implementing and developing pharmacovigilance systems. Countries such as Somalia, Djibouti, Mauritania, have no pharmacovigilance system or culture.



Daniela Di Cosmo has been working in the Pharmacovigilance field since 2013, firstly in Hospitals in Italy, and then abroad (Czech Republic, UK, Ireland and Denmark), handling all possible tasks in both clinical (all clinical trials' phases) and post-marketing. She has always operated on a global level, yet facing the possible new changes given by local legislations

Pharmacovigilance and Medical affairs ADR Reporting

Global Pharmacovigilance 2020, March 16-17, 2020, Sydney, Australia

Mohammed Ashar, Challenges of implementing PV processes in mena region

J Pharmacokinet Exp Her

ISSN: JPET, an open access journal

Volume S(1)